GSK shrinks Scynex­is deal af­ter de­lay in com­mer­cial­iza­tion of an­ti­fun­gal drug

Scynex­is will get less mon­ey in a mul­ti­mil­lion-dol­lar li­cense agree­ment with Glax­o­SmithK­line af­ter po­ten­tial cross-con­t­a­m­i­na­tion in the man­u­fac­tur­ing of its an­ti­fun­gal drug de­layed com­mer­cial­iza­tion.

Scynex­is said in SEC fil­ings it has al­ready re­ceived an up­front pay­ment of $90 mil­lion and one de­vel­op­ment mile­stone pay­ment of $25 mil­lion in the deal to li­cense ibrex­a­fungerp, ap­proved as Brex­afemme to treat vagi­nal yeast in­fec­tions, to GSK. GSK will al­so pay roy­al­ties based on an­nu­al sales, the terms of which were left un­changed.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER